{"filing":{"accession_number":"0001213900-26-091445","cik":"0001611747","ticker":"SCNI","company_name":"Scinai Immunotherapeutics Ltd.","form":"6-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"ea0302675-6k_scinai.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390026091445/ea0302675-6k_scinai.htm"},"events":[{"id":28443,"run_id":26020,"accession_number":"0001213900-26-091445","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"summary":"The Company announced an ADS ratio change (1-for-10 reverse split) effective August 21, 2026, explicitly to \"regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per ADS for continued listing.\" The disclosure acknowledges that the Company's stock price had fallen below the minimum bid price threshold and that there is no assurance the reverse split will restore compliance. This is a material delisting-risk disclosure under Item 3.01 equivalent, as it signals the registrant's failure to satisfy a continued listing rule and the remedial action taken.","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-08-19","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":30391,"accession_number":"0001213900-26-091445","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The Company announced an ADS ratio change (1-for-10 reverse split) effective August 21, 2026, explicitly to \"regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per ADS for continued listing.\" The disclosure acknowledges that the Company's stock price had fallen below the minimum bid price threshold and that there is no assurance the reverse split will restore compliance. This is a material delisting-risk disclosure under Item 3.01 equivalent, as it signals the registrant's failure to satisfy a continued listing rule and the remedial action taken.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T13:25:37.503638+00:00","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-08-19"}]}